Endonovo Therapeutics, Inc. (ENDV) stock
ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $135.08KP/E –Yield –
Endonovo Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Endonovo Therapeutics's shares outstanding was 1.35B at Sep 30, 2023. For fiscal 2022 it was 139M, up 132.6% from the year before. Over ten years it grew 11.2% a year on average. The highest annual figure on record is 242M in fiscal 2017.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 139M | +132.6% |
| FY2021 | Dec 31, 2021 | 60M | +389.8% |
| FY2020 | Dec 31, 2020 | 12M | +1651.9% |
| FY2019 | Dec 31, 2019 | 1M | +92.4% |
| FY2018 | Dec 31, 2018 | 0M | -99.9% |
| FY2017 | Dec 31, 2017 | 242M | +106.2% |
| FY2016 | Dec 31, 2016 | 117M | +21.2% |
| FY2015 | Dec 31, 2015 | 97M | +219.7% |
| FY2014 | Dec 31, 2014 | 30M | +4046.0% |
| FY2013 | Dec 31, 2013 | 1M | -98.5% |
| FY2012 | Dec 31, 2012 | 48M | +961.5% |
| FY2011 | Dec 31, 2011 | 5M | 0.0% |
| FY2010 | Dec 31, 2010 | 5M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | 1.35B | +779.4% |
| Q2 FY2023 | Jun 30, 2023 | 1.35B | +905.3% |
| Q1 FY2023 | Mar 31, 2023 | 1.74B | +2106.3% |
| Q4 FY2022 | Dec 31, 2022 | 189M | +157.7% |
| Q3 FY2022 | Sep 30, 2022 | 154M | +131.7% |
| Q2 FY2022 | Jun 30, 2022 | 134M | +129.7% |
| Q1 FY2022 | Mar 31, 2022 | 79M | +90.1% |
| Q4 FY2021 | Dec 31, 2021 | 73M | +267.2% |
| Q3 FY2021 | Sep 30, 2021 | 66M | +310.8% |
| Q2 FY2021 | Jun 30, 2021 | 58M | +494.8% |
| Q1 FY2021 | Mar 31, 2021 | 42M | +248.6% |
| Q4 FY2020 | Dec 31, 2020 | 20M | +2006.5% |
| Q3 FY2020 | Sep 30, 2020 | 16M | +1976.2% |
| Q2 FY2020 | Jun 30, 2020 | 10M | +1602.7% |
| Q1 FY2020 | Mar 31, 2020 | 12M | +2375.1% |
| Q4 FY2019 | Dec 31, 2019 | 1M | -99.7% |
| Q3 FY2019 | Sep 30, 2019 | 1M | -99.8% |
| Q2 FY2019 | Jun 30, 2019 | 1M | -99.8% |
| Q1 FY2019 | Mar 31, 2019 | 0M | -99.8% |
| Q3 FY2018 | Sep 30, 2018 | 369M | +40.1% |
| Q2 FY2018 | Jun 30, 2018 | 348M | +5.2% |
| Q1 FY2018 | Mar 31, 2018 | 328M | +102.9% |
| Q4 FY2017 | Dec 31, 2017 | 307M | +138.8% |
| Q3 FY2017 | Sep 30, 2017 | 264M | +142.1% |
| Q2 FY2017 | Jun 30, 2017 | 331M | +290.0% |
| Q1 FY2017 | Mar 31, 2017 | 161M | +255.6% |
| Q4 FY2016 | Dec 31, 2016 | 129M | +16260.6% |
| Q1 FY2016 | Jun 30, 2016 | 109M | +26.6% |
| Q1 FY2015 | Mar 31, 2015 | 85M | +16.1% |
| Q3 FY2014 | Sep 30, 2014 | 45M | -34.0% |
| Q2 FY2014 | Jun 30, 2014 | 1M | -98.3% |
| Q1 FY2014 | Mar 31, 2014 | 86M | – |
| Q3 FY2013 | Sep 30, 2013 | 73M | – |
| Q2 FY2013 | Jun 30, 2013 | 69M | – |
| Q1 FY2013 | Mar 31, 2013 | 47M | – |
See a number that looks wrong?